Shacham Sharon 4
4 · Acrivon Therapeutics, Inc. · Filed May 20, 2026
Research Summary
AI-generated summary of this filing
Acrivon (ACRV) Director Shacham Sharon Receives RSU Award (9,366)
What Happened
Shacham Sharon, a director of Acrivon Therapeutics (ACRV), received an award of 9,366 restricted stock units (RSUs) on May 18, 2026. The RSUs were granted at $0.00 (standard for RSU awards) and will convert to one share of common stock per RSU upon vesting. This is a grant/award (transaction code A), not a purchase or sale.
Key Details
- Transaction date: 2026-05-18; Form 4 filed 2026-05-20 (appears timely).
- Grant: 9,366 RSUs; grant price reported as $0.00.
- Vesting: RSUs vest in full on May 18, 2027, subject to continuous service through the vesting date (per footnote).
- Shares owned after transaction: not specified in the filing.
- Footnote: RSUs represent contingent rights to receive one share of common stock each upon vesting. No 10b5‑1, tax withholding, or sale reported.
Context
RSU grants are common director compensation and do not involve immediate cash changing hands or an immediate change in share ownership until vesting. Because these are awards, they signal potential future ownership if the director remains in service through the vesting date, but do not by themselves indicate buying or selling sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-18+9,366→ 9,366 total
Footnotes (1)
- [F1]These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.